Biologics have revolutionized the management of moderate-to-severe psoriasis by specifically targeting immune pathways involving tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23) [59]. This evidence concerns the gene IL37 and psoriasis.